CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis)

European Journal of Haematology

Volumn 80, Issue 6, 2008, Pages 477-482

  Magnus, Björkholm ^a   Tomas, Andersson ^b,c   Anders, Ahlbom ^b,c   Eva, Ösby ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Stockholm Centre of Public Health   (Sweden)

Author keywords

Aggressive; Chemotherapy; CHOP; CNOP; Lymphoma; Meta analysis

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, NON-HODGKIN; MITOXANTRONE; PREDNISOLONE; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 43549089062     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01062.x     Document Type: Article

References (36)

1. DeVita VT Jr., Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975 1:248 50.
2. Whitelaw DM, Kim HS. Vincristine in the treatment of neoplastic disease. Can Med Assoc J 1964 90:1385 9.
3. Hyman GA, Cassileth PA. Efficacy of cyclophosphamide in the management of reticulum cell sarcoma. Cancer 1966 19:1386 92.
4. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970 30:2572 82.
5. Gottlieb JA, Gutterman JU, McCredie KB, Rodriguez V, Frei E III. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 1973 33:3024 8.
6. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976 38:1484 93.
7. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glück JH, Coltman CA Jr., Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993 328:1002 6.
8. Kimby E, Brandt L, Nygren P, Glimelius B. SBU-group, Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol 2001 40:198 212.
9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346:235 42.
10. Osby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkholm M Nordic Lymphoma Group. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003 101:3840 8.
11. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004 104:634 41.
12. Von Hoff DD, Layard MW, Basa P, Davis HL Jr., Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979 91:710 7.
13. Kimmick GG, Fleming R, Muss HB, Balducci L. Cancer chemotherapy in older adults, a tolerability perspective. Drugs Aging 1997 10:34 49.
14. Armitage JO. The role of mitoxantrone in non-Hodgkin's lymphoma. Oncology 2002 16:490 7.
15. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 2005 10:150 9.
16. Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukat G, Reisman A, Schoch I. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988 6:1611 20.
17. Delozier T, Vernhes JC. Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature. Bull Cancer 1991 78:1013 25.
18. Case DC, Wolff S, Bennett JM. Phase III comparative trial of m-B-(doxorubicin) COD (m-BACOD) and m-B-Novantrone COD (m-BNCOD) in the treatment of intermediate/high grade lymphoma. Blood 1988 72 (Suppl. 1 239a (abstract).
19. Guglielmi C, Gherlinzoni F, Amadori S, Mazza P, Mantovani L, Lauria F, Martelli M, Zinzani PL, Greco V, Poletti G. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Haematologica 1989 74:563 9.
20. Mainwaring PN, Cunningham D, Gregory W, Hoskin P, Hancock B, Norton AJ, Maclennan K, Smith P, Hudsom GV, Linch D. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with highgrade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood 2001 97:2991 7.
21. Kimura I, Ohnoshi T, Masaoka T, Sampi K, Namba K. A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result. Gan To Kagaku Ryoho 1986 13:2813 9.
22. Bessell EM, Burton A, Haynes AP, et al. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Ann Oncol 2003 14:258 67.
23. Chuang MW, Tzeng CH, Chiou TJ, Chiu CF, Hsieh RK, Liu JH, Chen PM. A comparative trial of C-novantrone OP(CNOP) vs C-adriamycin OP(CHOP) in the treatment of stage II-IV malignant lymphoma - the preliminary report. Zhonghua Yi Xue Za Zhi (Taipei) 1988 41:51 6.
24. Pangalis GA, Vassilakopoulos TP, Michalis E, et al. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003 44:635 44.
25. Pavlovsky S, Santarelli MT, Erazo A, Diaz-Maqueo JC, Somoza N, Lluesma Goñalons M, Cervantes G, Garcia Vela EL, Corrade C, Magnasco H. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol 1992 3:205 9.
26. Bezwoda W, Rastogi RB, Erazo Valla A, Diaz-Maqueo JC, Pavlovsky S, Morioka H, Resegotti L, Rueckle H, Somoza N, Moreno-Noqueria JA. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. Eur J Cancer 1995 31A:903 11.
27. Brusamolino E, Bertini M, Guidi S, Vitolo U, Inverardi D, Merante S, Colombo A, Resegotti L, Bernasconi C, Ferrini PR. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. Haematologica 1988 73:217 22.
28. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995 13:2530 9.
29. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999 17:1244. Review.
30. Ösby E, Taube A, Cavallin-Ståhl E, Hagberg H, Björkholm M. Reproducibility of tumor response evaluation in patients with high-grade non-Hodgkin lymphoma. Med Oncol 2001 18:137 40.
31. Weiss RB, Gill GG, Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 2001 19:2771 7.
32. Lyman GH, Dale DC, Friedberg J, Carwford J, Risher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: an nationwide study. J Clin Oncol 2004 22:4302 11.
33. Borchmann P, Schnell R. The role of pixantrone in the treatment of non-Hodgkin's lymphoma. Expert Opin Investig Drugs 2005 14:1055 61.
34. Weiss RB. Mitoxantrone: its development and role in clinical practice. Oncology (Williston Park) 1989 6:135 41.
35. Economopoulos T, Fountzilas G, Pavlidis N, Kalantzis D, Papageorgiou E, Christodoulou C, Hamilos G, Nicolaides C, Dimopoulos M. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J 2003 4:110 5.
36. Rigacci L, Carpaneto A, Alterini R, Carrai V, Bernardi F, Bellesi G, Longo G, Bosi A, Rossi Ferrini P. Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results. Cancer 2003 97:97 104.